US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

9.20

+0.23002.56%

Post-market: 9.14-0.0600-0.65%17:13 EDT

Volume:269.33K

Turnover:2.48M

Market Cap:3.12B

PE:-436.02

High:9.31

Open:9.18

Low:8.93

Close:8.97

52wk High:20.00

52wk Low:6.28

Shares:339.00M

Float Shares:272.00M

Volume Ratio:1.02

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0211

EPS(LYR):-0.0211

ROE:-1.85%

ROA:1.15%

PB:7.51

PE(LYR):-436.02

Loading ...

Overview Company News Filings

Stock Track | Telix Pharmaceuticals Soars 8.79% in Pre-market on Conference Participation and Pipeline Advancement Plans

Telix to Participate in Oppenheimer and TD Cowen Conferences

Telix Pharmaceuticals Plans to Reinvest Earnings to Advance Therapeutic Pipeline, CEO Says; Shares Up 8%

MT Newswires Live

FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

Telix Pharmaceuticals Swings to 2025 Loss, Posts Higher Revenue

MT Newswires Live

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Its European Filing For Glioma Imaging Agent TLX101-Px

Simply Wall St.

Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

Earning Preview: Telix Pharmaceuticals Ltd. (Uplisting) this quarter’s revenue is expected to increase by 63.53%, and institutional views are bullish

Telix Pharmaceuticals Says JPMorgan Chase Lifts Stake

MT Newswires Live

Citi Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Telix Pharmaceuticals (TLPPF) Gets a Buy from Citi

Telix Full Year Results 2025 Investor Webcast Notification

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Regulatory Setbacks And Rising Investor Caution

Simply Wall St.

Telix Pharmaceuticals Chair Resigns as Board Installs Interim Successor

Does Asian TLX591-Px Expansion Progress Change The Bull Case For Telix Pharmaceuticals (ASX:TLX)?

Simply Wall St.

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Key China And US Prostate Cancer Milestones

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (OtherTLPPF) and Olema Pharmaceuticals (OLMA)

How China NMPA NDA Acceptance and US BiPASS Milestone At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story

Simply Wall St.

Challenger Exits Substantial Shareholder Position in Telix Pharmaceuticals

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TLX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":9.2,"timestamp":1774641600000,"preClose":8.97,"halted":0,"volume":269334,"hourTrading":{"tag":"盘后","latestPrice":9.14,"preClose":9.2,"latestTime":"17:13 EDT","volume":270,"amount":2464.34,"timestamp":1774645980687,"change":-0.06,"changeRate":-0.006522,"amplitude":0.006522},"delay":0,"changeRate":0.025641025641025487,"floatShares":272000000,"shares":339000000,"eps":-0.0211,"marketStatus":"Market Closed","change":0.23,"latestTime":"03-27 16:00:00 EDT","open":9.18,"high":9.308,"low":8.93,"amount":2479734.975276,"amplitude":0.04214,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0211,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":8.97,"preHourTrading":{"tag":"盘前","latestPrice":9.2,"preClose":8.97,"latestTime":"09:29 EDT","volume":5567,"amount":51061.314514,"timestamp":1774618199071,"change":0.23,"changeRate":0.025641,"amplitude":0.020067},"postHourTrading":{"tag":"盘后","latestPrice":9.14,"preClose":9.2,"latestTime":"17:13 EDT","volume":270,"amount":2464.34,"timestamp":1774645980687,"change":-0.06,"changeRate":-0.006522,"amplitude":0.006522},"volumeRatio":1.017782013599113},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":272000000,"roa":"1.15%","roe":"-1.85%","lyrEps":-0.0211,"volumeRatio":1.017782013599113,"shares":339000000,"dividePrice":0,"high":9.308,"amplitude":0.04214,"preClose":8.97,"low":8.93,"week52Low":6.28,"pbRate":"7.51","psRate":"3.88","week52High":20,"institutionHeld":0,"latestPrice":9.2,"eps":-0.0211,"divideRate":0,"volume":269334,"delay":0,"ttmEps":-0.0211,"open":9.18,"prevYearClose":7.49,"prevWeekClose":8.75,"prevMonthClose":7.25,"prevQuarterClose":7.49,"fiveDayClose":8.75,"twentyDayClose":7.25,"sixtyDayClose":7.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"TLX","fiscalQuarterEnding":"2025/12","expectedEps":0.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1758254400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2026-03-27","current":-436.018957,"percent":0,"low":-448.04178,"twenty":163.181765,"median":182.800475,"eighty":285.212188,"high":383.853933,"avg":170.469237,"sd":166.962779,"marketCap":3192297684.03},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6},{"date":"2025-08-08","current":119.575098,"twenty":163.364827,"median":173.121803,"eighty":185.031841,"marketCap":3879545892.37},{"date":"2025-08-15","current":118.626089,"twenty":162.985468,"median":172.816584,"eighty":184.520886,"marketCap":3844757658.1},{"date":"2025-08-22","current":367.342977,"twenty":162.565192,"median":172.783145,"eighty":185.031841,"marketCap":3983594342.69},{"date":"2025-08-29","current":297.28853,"twenty":162.917681,"median":173.086118,"eighty":186.439488,"marketCap":3223899680.91},{"date":"2025-09-05","current":280.194275,"twenty":162.97191,"median":173.155042,"eighty":187.353158,"marketCap":3038523660.62},{"date":"2025-09-12","current":284.24913,"twenty":163.053254,"median":173.392729,"eighty":189.722035,"marketCap":3082495919.22},{"date":"2025-09-19","current":299.993591,"twenty":163.181765,"median":173.840405,"eighty":192.411646,"marketCap":3253234303.96},{"date":"2025-09-26","current":303.368871,"twenty":163.269039,"median":174.34097,"eighty":195.332201,"marketCap":3289837005.56},{"date":"2025-10-03","current":316.222238,"twenty":163.331056,"median":174.844246,"eighty":197.182743,"marketCap":3429223360.77},{"date":"2025-10-10","current":308.943311,"twenty":163.584606,"median":175.579785,"eighty":198.432664,"marketCap":3350288154.24},{"date":"2025-10-17","current":337.724829,"twenty":164.112905,"median":175.99796,"eighty":200.117317,"marketCap":3662404902.51},{"date":"2025-10-24","current":335.676999,"twenty":164.422238,"median":176.508379,"eighty":204.373856,"marketCap":3640197520.67},{"date":"2025-10-31","current":328.898919,"twenty":164.871944,"median":177.318176,"eighty":280.077091,"marketCap":3566693671.28},{"date":"2025-11-07","current":302.845362,"twenty":165.230483,"median":178.059203,"eighty":285.744085,"marketCap":3284159889.46},{"date":"2025-11-14","current":289.051675,"twenty":165.371547,"median":178.295984,"eighty":290.299055,"marketCap":3134576370.19},{"date":"2025-11-21","current":278.19044,"twenty":165.561349,"median":179.014446,"eighty":289.541689,"marketCap":3016793389.39},{"date":"2025-11-28","current":310.533522,"twenty":165.669807,"median":179.412236,"eighty":291.060611,"marketCap":3367532955.32},{"date":"2025-12-05","current":306.208941,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"marketCap":3320635708.33},{"date":"2025-12-12","current":286.055209,"twenty":165.873166,"median":180.584513,"eighty":295.905706,"marketCap":3102081667.78},{"date":"2025-12-19","current":244.707348,"twenty":165.940952,"median":181.091444,"eighty":294.691227,"marketCap":2653691145.03},{"date":"2025-12-26","current":248.848958,"twenty":166.394684,"median":181.60348,"eighty":294.390689,"marketCap":2698604201.29},{"date":"2026-01-02","current":236.757004,"twenty":166.574536,"median":182.507221,"eighty":293.840477,"marketCap":2567474872.89},{"date":"2026-01-09","current":234.880062,"twenty":166.797362,"median":182.734458,"eighty":292.111558,"marketCap":2547120662.92},{"date":"2026-01-16","current":240.619616,"twenty":166.998047,"median":183.212494,"eighty":291.104403,"marketCap":2609362374.53},{"date":"2026-01-23","current":233.793317,"twenty":167.188576,"median":183.578507,"eighty":290.823686,"marketCap":2535335622.99},{"date":"2026-01-30","current":230.611959,"twenty":167.428163,"median":183.988776,"eighty":290.419247,"marketCap":2500835870.83},{"date":"2026-02-06","current":214.320895,"twenty":167.500324,"median":184.979028,"eighty":290.056234,"marketCap":2324169939.4},{"date":"2026-02-13","current":194.105832,"twenty":167.571527,"median":185.74722,"eighty":289.461299,"marketCap":2104950801.53},{"date":"2026-02-20","current":-349.931165,"twenty":167.550165,"median":186.245055,"eighty":289.186438,"marketCap":2493259551.93},{"date":"2026-02-27","current":-337.576812,"twenty":166.94361,"median":185.358176,"eighty":288.884688,"marketCap":2405234781.68},{"date":"2026-03-06","current":-357.014534,"twenty":165.886723,"median":184.229774,"eighty":287.796958,"marketCap":2543728559.75},{"date":"2026-03-13","current":-380.87359,"twenty":165.371547,"median":183.661424,"eighty":286.105301,"marketCap":2713724328.68},{"date":"2026-03-20","current":-427.441295,"twenty":164.112905,"median":183.427298,"eighty":285.888656,"marketCap":3045519229.47},{"date":"2026-03-27","current":-448.04178,"twenty":163.181765,"median":182.800475,"eighty":285.212188,"marketCap":3192297684.03}],"updateTime":1774741125016},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1169143084","title":"Stock Track | Telix Pharmaceuticals Soars 8.79% in Pre-market on Conference Participation and Pipeline Advancement Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=1169143084","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169143084?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:28","pubTimestamp":1771590514,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. saw its stock surge 8.79% during the pre-market trading session on Friday.The significant upward movement follows the company's announcement that it will participate in two...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX"],"gpt_icon":0},{"id":"2612261413","title":"Telix to Participate in Oppenheimer and TD Cowen Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2612261413","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612261413?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:00","pubTimestamp":1771588800,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Feb.  20, 2026  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming Oppenheimer 36th Annual Healt","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/20/3241845/0/en/Telix-to-Participate-in-Oppenheimer-and-TD-Cowen-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TD","BK4585","BK4526","TLX","ASX","BK4543","BK4141","BK4566","BK4127","COWN","OPY","BK4207","BK4139"],"gpt_icon":0},{"id":"2612237607","title":"Telix Pharmaceuticals Plans to Reinvest Earnings to Advance Therapeutic Pipeline, CEO Says; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612237607","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612237607?lang=en_us&edition=fundamental","pubTime":"2026-02-20 09:21","pubTimestamp":1771550503,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  Chief Executive Christian Behrenbruch said the company is prioritizing the advancement of its therapeutic pipeline, which includes three pivotal stage trials in prostate, kidney, and brain cancer, by reinvesting earnings, according to a Friday filing with the Australian bourse.The company also plans to expand its precision medicine growth through label expansion studies and new product launches, per the filing.Shares rose nearly 8% in midday trade Friday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"gpt_icon":0},{"id":"2612231047","title":"FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2612231047","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612231047?lang=en_us&edition=fundamental","pubTime":"2026-02-20 07:27","pubTimestamp":1771543620,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces its financial results for the year ended December31, 2025.Group performance2: Double-digit revenue growth and positive adjusted operating cash flow. Revenue of US$803.8 million, up by 56%3 and achieving upsized full year guidance4.US$157.1 million invested in research and development (R&D) product development for late-stage therapeutics and precision medicine pipeline assets5, in line with stated FY 2025 guidance.Adjusted EBITDA6 of US$39.5 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure and research and development (R&D).Year-end cash balance of US$141.9 million following US$246.4 million of strategic investments (M&A) and cash generated from operating activities of US$34.5 million before the final contingent consideration payment to Advanced Nuclear Medicine Ingredients  of US$51.8 million7","market":"nz","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/fy-2025-results-strong-commercial-growth-focused-pipeline-investment-302693191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7095","BK4139","TAT","BK7067","BK4543","BK7116","BLA.AU","BK7039","CE","ASX","ASX.AU","GBM.AU","TMS.AU","BK7104","BK4588","TLX","SEC.AU","BK4526","BK7506","BK4109","BK4585","BK4141","TAT.AU"],"gpt_icon":0},{"id":"2612318752","title":"Telix Pharmaceuticals Swings to 2025 Loss, Posts Higher Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2612318752","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612318752?lang=en_us&edition=fundamental","pubTime":"2026-02-20 06:52","pubTimestamp":1771541574,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  reported Friday that it swung to a loss of $0.0211 in 2025 from a profit of $0.0976 a year earlier.Analysts polled by FactSet expected the company to break even.Revenue for the 12 months ended Dec. 31, 2025, was $803.8 million, compared with $516.6 million a year earlier. Analysts surveyed by FactSet expected $804 million.The company expects 2026 group revenue to range from $950 million to $970 million. Analysts polled by FactSet expect $930.8 million.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"gpt_icon":0},{"id":"2612470397","title":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Its European Filing For Glioma Imaging Agent TLX101-Px","url":"https://stock-news.laohu8.com/highlight/detail?id=2612470397","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612470397?lang=en_us&edition=fundamental","pubTime":"2026-02-19 14:25","pubTimestamp":1771482318,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has lodged a marketing authorization application in Europe for TLX101-Px, an 18F-FET PET imaging agent for glioma. The company is targeting broader access and more consistent diagnostic quality across major markets.\nSee our latest analysis for Telix Pharmaceuticals.\nTelix’s A$8.88 share price comes after a 1-day share price return of 0.45%, but a 30-day share price return decline of 21.28% and a 1-year total shareholder return decline of 66.89%, suggesting...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-its-e","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-its-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TLX.AU","TLX","BK7067"],"gpt_icon":0},{"id":"2612959514","title":"Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2612959514","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612959514?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:55","pubTimestamp":1771365300,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Feb.  18, 2026  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorizatio","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239824/0/en/Telix-Submits-European-Marketing-Authorization-Application-for-TLX101-Px-for-Brain-Cancer-Imaging.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","TLX","BK4585","BK4526","BK4543","BK4139","MAA","BK4141","BK4215","ASX"],"gpt_icon":0},{"id":"1197899035","title":"Earning Preview: Telix Pharmaceuticals Ltd. (Uplisting) this quarter’s revenue is expected to increase by 63.53%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1197899035","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197899035?lang=en_us&edition=fundamental","pubTime":"2026-02-13 10:28","pubTimestamp":1770949735,"startTime":"0","endTime":"0","summary":"Abstract Telix Pharmaceuticals Ltd. (Uplisting) is scheduled to report quarterly results on February 20, 2026 after market close, with investor focus on revenue momentum, margin mix, EPS trajectory,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Telix Pharmaceuticals Ltd. (Uplisting) this quarter’s revenue is expected to increase by 63.53%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX"],"gpt_icon":0},{"id":"2610450724","title":"Telix Pharmaceuticals Says JPMorgan Chase Lifts Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2610450724","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610450724?lang=en_us&edition=fundamental","pubTime":"2026-02-09 11:30","pubTimestamp":1770607852,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  received notice that JPMorgan Chase and its affiliates increased their holdings in the company to 6.62% from 5.54%, according to a Monday filing with the Australian bourse.JPMorgan Chase and its affiliates now own 22.4 million shares in the company, the filing said.The company's shares fell around 1% in recent Monday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B775SV38.USD","LU0320765489.SGD","LU0170899867.USD","LU0882574139.USD","IE00BDCRKT87.USD","LU0211328371.USD","LU2054465674.USD","LU0211326755.USD","BK4585","LU0310799852.SGD","LU0820561818.USD","IE00B3S45H60.SGD","LU0070302665.USD","IE00BKVL7J92.USD","IE00BWXC8680.SGD","BK4504","LU0496365809.HKD","LU1064131342.USD","LU2462157665.USD","LU0345769631.USD","LU2242649171.HKD","LU0820561909.HKD","IE00BYXW3230.USD","BK4139","LU0106831901.USD","LU2552382058.USD","LU1116320901.HKD","IE00B1BXHZ80.USD","LU1032466523.USD","LU0943347566.SGD","LU0976567544.SGD","LU0971096721.USD","IE00BJTD4V19.USD","IE00BDRTCR15.USD","LU0345770308.USD","TLX.AU","LU2237443465.HKD","IE00BJTD4N35.SGD","LU0208291251.USD","LU1670628061.USD","LU2237443382.USD","LU0323591593.USD","LU1244550577.SGD","TLX","LU1974910355.USD","LU1670627923.USD","LU0683600562.USD","LU1894683348.USD","LU2237443622.USD","LU0417517546.SGD"],"gpt_icon":0},{"id":"2610541503","title":"Citi Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610541503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610541503?lang=en_us&edition=fundamental","pubTime":"2026-02-09 06:35","pubTimestamp":1770590134,"startTime":"0","endTime":"0","summary":"Citi analyst Laura Sutcliffe maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$34.00. According to TipRanks, Sutcl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-reaffirms-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-reaffirms-their-buy-rating-on-telix-pharmaceuticals-tlppf-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX"],"gpt_icon":0},{"id":"2608386249","title":"Telix Pharmaceuticals (TLPPF) Gets a Buy from Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2608386249","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608386249?lang=en_us&edition=fundamental","pubTime":"2026-02-04 06:36","pubTimestamp":1770158167,"startTime":"0","endTime":"0","summary":"In a report released today, Laura Sutcliffe from Citi maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$34.00. Sutcliffe c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-gets-a-buy-from-citi-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-gets-a-buy-from-citi-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX","BK4139"],"gpt_icon":0},{"id":"2608383457","title":"Telix Full Year Results 2025 Investor Webcast Notification","url":"https://stock-news.laohu8.com/highlight/detail?id=2608383457","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608383457?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:38","pubTimestamp":1770154680,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited  advises that it will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT .An investor webcast and conference call will be held at 9:30 a.m. AEDT, Friday 20 February 2026 .Annie Kasparian Telix Pharmaceuticals Limited Director Investor Relations and Corporate Communications Email: [emailprotected]. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited  in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements , wheth","market":"sg","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-full-year-results-2025-investor-webcast-notification-302678211.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEC.AU","ASX.AU","TLX","BK7039","BK7067","BK4543","BK4526","BK4139","TLX.AU","BK4141","ASX"],"gpt_icon":0},{"id":"2608825088","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Regulatory Setbacks And Rising Investor Caution","url":"https://stock-news.laohu8.com/highlight/detail?id=2608825088","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608825088?lang=en_us&edition=fundamental","pubTime":"2026-02-03 12:51","pubTimestamp":1770094266,"startTime":"0","endTime":"0","summary":"Regulatory setbacks put Telix Pharmaceuticals (ASX:TLX) under closer investor scrutiny\nTelix Pharmaceuticals (ASX:TLX) is back in focus after three FDA rejections and an ongoing SEC investigation. These events have coincided with a sharp share price pullback and heightened regulatory risk.\nSee our latest analysis for Telix Pharmaceuticals.\nThe regulatory setbacks have coincided with a steep reset in sentiment, with a 90 day share price return of a 33.46% decline and a 1 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-regul","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-regul","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TLX.AU","TLX","BK7067"],"gpt_icon":0},{"id":"2608815111","title":"Telix Pharmaceuticals Chair Resigns as Board Installs Interim Successor","url":"https://stock-news.laohu8.com/highlight/detail?id=2608815111","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608815111?lang=en_us&edition=fundamental","pubTime":"2026-02-03 06:37","pubTimestamp":1770071846,"startTime":"0","endTime":"0","summary":"An announcement from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals has announced the resignation of Board Chair and N...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-chair-resigns-as-board-installs-interim-successor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-chair-resigns-as-board-installs-interim-successor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2608131070","title":"Does Asian TLX591-Px Expansion Progress Change The Bull Case For Telix Pharmaceuticals (ASX:TLX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2608131070","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608131070?lang=en_us&edition=fundamental","pubTime":"2026-01-31 23:41","pubTimestamp":1769874099,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals reported that China’s NMPA has accepted the New Drug Application for its prostate cancer imaging agent TLX591-Px (Illuccix®), supported by a pivotal Phase 3 study in Chinese patients with biochemical recurrence.\nIn parallel, the first patient has now been dosed in a Phase 3 registration study in Japan, highlighting Telix’s push to expand TLX591-Px across major Asian nuclear medicine markets in prostate cancer care.\nWe’ll next examine how this progress toward broader...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-asian-tlx591-px-expansion-progress-change-the-bull-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-asian-tlx591-px-expansion-progress-change-the-bull-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","BK4097","BK7067","TLX.AU","PRGS","BK4139","TLX"],"gpt_icon":0},{"id":"2607722363","title":"First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2607722363","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607722363?lang=en_us&edition=fundamental","pubTime":"2026-01-29 07:43","pubTimestamp":1769643780,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ --Telix Pharmaceuticals Limited  today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px  for prostate cancer imaging in Japanese patients. The patient was dosed at Shonan Kamakura General Hospital  in Kamakura, Japan.Illuccix Japan[1] is a Phase 3 prospective, open-label, multicenter study designed to evaluate the detection efficacy and safety profile of 68Ga-PSMA-11 PET/CT[2] in Japanese patients with biochemically recurrent  prostate cancer following prior radical prostatectomy. The study will enroll up to 105 Japanese men at 11 sites and data are intended to support a future marketing authorization application for TLX591-Px in Japan.The primary objective of the study is to compare the sensitivity of 68Ga-PSMA-11 PET/CT to conventional imaging  for the detection of metastatic lesions. Secondary objectives include evaluating diagnostic performance for local and distant lesions, safety and to","market":"other","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/first-patient-dosed-in-pivotal-phase-3-study-of-tlx591-px-illuccix-for-prostate-cancer-imaging-in-japanese-patients-302673282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","SEC.AU","BCR","BK7039","BK4141","BK4543","ASX.AU","ASX","BK4139","BK4526","BK7067","TLX.AU"],"gpt_icon":0},{"id":"2606614203","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Key China And US Prostate Cancer Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2606614203","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606614203?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:33","pubTimestamp":1769470391,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) is back in focus after Chinese regulators accepted a New Drug Application for its Illuccix prostate cancer imaging agent, and the company reported first patient dosing in a US Phase 3 diagnostic trial.\nSee our latest analysis for Telix Pharmaceuticals.\nDespite the regulatory momentum in China and the US, Telix’s share price return over the past 90 days shows a 34.31% decline, contributing to a 60.23% drop in 1-year total shareholder return. However, the 5-year...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-key-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-key-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TLX.AU","BK7067","TLX"],"gpt_icon":0},{"id":"2606224485","title":"Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (OtherTLPPF) and Olema Pharmaceuticals (OLMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606224485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606224485?lang=en_us&edition=fundamental","pubTime":"2026-01-27 06:50","pubTimestamp":1769467822,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Telix Pharmaceuticals (TLPPF – Research Report) and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-telix-pharmaceuticals-othertlppf-and-olema-pharmaceuticals-olma-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-telix-pharmaceuticals-othertlppf-and-olema-pharmaceuticals-olma-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4505","LU0128526141.USD","BK4137","BK4139","LU0029874061.USD","BK4581","HCSG","OLMA","BK4588","BK4585","TLX","XBI","LABU"],"gpt_icon":0},{"id":"2605595236","title":"How China NMPA NDA Acceptance and US BiPASS Milestone At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2605595236","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605595236?lang=en_us&edition=fundamental","pubTime":"2026-01-24 14:32","pubTimestamp":1769236341,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently reported that China’s NMPA accepted the New Drug Application for its prostate cancer imaging agent TLX591-Px, while the first U.S. patient was dosed in the BiPASS Phase 3 trial assessing Illuccix and Gozellix in pre-biopsy diagnosis.\nEarly data showing high positive predictive value in Chinese patients and a trial aimed at reducing unnecessary biopsies highlight how Telix’s PSMA-PET portfolio could influence prostate cancer care pathways across major...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-china-nmpa-nda-acceptance-and-us-bipass-milestone-at-tel","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-china-nmpa-nda-acceptance-and-us-bipass-milestone-at-tel","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4139","TLX","TLX.AU"],"gpt_icon":0},{"id":"2605475425","title":"Challenger Exits Substantial Shareholder Position in Telix Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2605475425","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605475425?lang=en_us&edition=fundamental","pubTime":"2026-01-23 13:12","pubTimestamp":1769145171,"startTime":"0","endTime":"0","summary":"Challenger ( ($AU:CGF) ) has shared an announcement. Challenger Limited has notified the ASX that it has ceased to be a substantial holder in Telix...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/challenger-exits-substantial-shareholder-position-in-telix-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/challenger-exits-substantial-shareholder-position-in-telix-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":126,"code":"91000000","status":"200"}]}}